Former Senator Ben Sasse announced his stage 4 pancreatic cancer diagnosis in 2025, calling it "a death sentence" while ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Researchers demonstrated that newly developed molecules designed to block an immune checkpoint can trigger a powerful immune response against tumors. Scientists at MIT and Stanford University have ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Lung cancer patients who received IV immunotherapy doses earlier in the day tended to live longer, researchers reported in a ...

Host-Related Determinants of Immunotherapy Response in NSCLC may include obesity, sarcopenia, metabolic comorbidities, sex, ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced a collaboration with the Institute for ...

A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...

This immunotherapy treatment holds promise beyond rectal cancer. In early studies of people with esophageal, bladder, or prostate tumors with the same molecular signature, 80 percent were cured.

Precision immunotherapy added to standard care and tailored to specific immune dysfunctions in sepsis improves organ dysfunction compared with placebo, a multinational phase 2 trial finds.